TYPE 2 AIRWAY INFLAMMATION AND INHIBITION OF BIOLOGICAL DRUGS IN ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Abstract

Asthma and chronic obstructive pulmonary disease are inflammatory airways diseases with an increasing prevalence worldwide. Each of these diseases is characterized by heterogeneity, that is, not only the different clinical course of the disease but also the pathogenesis of the disease and the response to treatment. To understand the heterogeneity of asthma and COPD, identify the phenotype of the disease and the endotype is particularly important to individualize the treatment of these diseases. Recently, special attention has been paid to type 2 airway inflammation, which is characterized by eosinophilia. Insufficient management of type 2 airway inflammation results in a severe course of illness, resistance to treatment, frequent exacerbations of the disease, and is associated with worse quality of life. A number of well-known biomarkers are associated with type 2 airway inflammation, and their use in clinical practice is essential. This review provides the summarized data on the pathways of the development of type 2 airway inflammation, the importance and need for biomarkers, the latest treatment options for type 2 airway inflammation.